

Antitubercular agents. Part 2: New thiolactomycin analogues active against *Mycobacterium tuberculosis*

Ahmed Kamal,^{a,*} Ahmad Ali Shaik,^a Rakesh Sinha,^b J. S. Yadav^a and Sudarshan K. Arora^b

^aDivision of Organic Chemistry, Indian Institute of Chemical Technology, Hyderabad 500007, India

^bLupin Laboratories Limited, Lupin Research Park, Pune 411042, India

Received 16 December 2004; accepted 29 January 2005

Abstract—Structurally modified analogues of naturally occurring antibiotic thiolactomycin, substituted at 4-position of the thiolactone ring have been prepared and evaluated for their antitubercular activity. Some of the compounds have exhibited potential activity against *Mycobacterium tuberculosis*.

© 2005 Elsevier Ltd. All rights reserved.

Mycobacterium tuberculosis, which causes tuberculosis, is the greatest single infection responsible for mortality worldwide, killing roughly two million people annually.¹ Current estimates indicate that one-third of world's population is with latent *M. tuberculosis*.² Despite the fact that it is treatable and preventable, the disease has been spreading at a steady rate over the past decade.³ The emergence of bacterial resistance to the multidrug resistant TB (MDRTB) of existing antitubercular agents has become a significant concern for the effective treatment of tuberculosis. The determination of whole-genome sequence of *M. tuberculosis*⁴ has pinpointed drug targets that have potential for improved therapy.⁵

Thiolactomycin (TLM, **1**) that has a thiolactone ring system is an antibiotic obtained from the fermentation broth of a strain of actinomycetes, which was identified as species of *Nocardia*,⁶ is active against in vitro Gram positive, Gram negative and anaerobic bacteria. Thiolactomycin is a unique molecule that exhibits selective activity against only the dissociable type II fatty acid synthetase (FAS) enzymes.⁷ TLM is a reversible inhibitor^{7a} of β -ketoacyl synthetase (KAS) of bacterial FAS systems including KAS I-III and acetyl coenzyme A (CoA): ACP transacylase activities in vitro and in vivo


in *E. coli*.⁸ Crystal structure of KAS I (Fab B from *E. coli*) bound with TLM reveals the essential enzyme–ligand binding interactions and establish the existence of hydrophobic and pantetheine binding pockets that are both unoptimally filled.⁹ Previous studies reveal that a number of TLM analogues with aliphatic side chains at 5-position of thiolactone ring have shown significant enhancement of activity against mycolate synthesis.^{10,11}

Recently, a number of biphenyl based¹² and acetylene based¹³ TLM analogues have been synthesized that exhibit significant activity against mtFabH fatty acid condensing enzyme. These results from earlier studies illustrate the importance of side-chain structure in TLM analogues. However, no efforts have been made for preparing analogues by substituting the 4-position of the thiolactone ring. Studies have also been carried out in this laboratory for the development of antitubercular compounds based on other class of prototypes.¹⁴ Therefore, in the present investigation an attempt has been made to prepare 4-substituted thiolactones and interestingly some of these analogues have exhibited promising in vitro antitubercular activity.

Thiolactone ring **2** which is the key intermediate for the preparation of such analogues has been synthesized by employing the procedure of Wang and Salvino.¹⁵ This method involves Claisen self ester condensation of methyl propionate **3** using KH to yield β -keto ester **4**. The selective bromination of **4** followed by nucleophilic substitution of bromine with thioacetic acid gives thio

Keywords: Thiolactomycin; *Mycobacterium tuberculosis*; Thiolactone.

* Corresponding author. Tel.: +91 40 2719 3157; fax: +91 40 2719 3189; e-mail addresses: ahmedkamal@iict.res.in; ahmedkamal@ins.iictnet.com




ester **6**, and finally cyclization to afford the 4-hydroxy thiolactone **2**. The required analogues have been prepared by the etherification of 4-hydroxy group of compound **2** with alkyl dihalides to afford terminal bromo substituted ether derivatives (**7a–f**). These bromo ether derivatives have been reacted with methyl thioglycolate, 1-methyl piperazine and morpholine to yield **8a–f**, **9a–f** and **10a–f**, respectively, with different carbon chain length spacers (Scheme 1).

All 24 compounds (**7a–f**, **8a–f**, **9a–f** and **10a–f**) were evaluated for antimycobacterial activity against four different mycobacterium (*M. tuberculosis* ATCC27294, *M. avium* ATCC 49601 and *M. intracellulare* ATCC 13950) species at a concentration of 50 and 25 µg by diffusion assay. Compounds **7f**,¹⁶ **8e**,¹⁷ **9a**¹⁸ and **9c** demonstrated good to mild inhibition of the mycobacterium cultures. The active compounds were then assayed for determination of minimum inhibitory concentration (MIC) against a variety of *M. tuberculosis* clinical isolates (drug sensitive and resistant) in agar dilution assay as per the NCCLS-M24-T2 recommendations. Briefly, 10 serial twofold dilutions of the compound/standard drug were made in DMSO and incorporated into Middlebrook 7H10 agar medium. Individual *M. tuberculosis* isolates at concentration of 1×10^7 CFU/mL were

spotted (3–5 µL/spot) on to the media plates. The plates were sealed and incubated at 37 °C for 3–4 weeks. Minimum inhibitory concentration (MIC) was recorded as the highest dilution of the compound(s) that completely inhibited the growth.

Compound **8e** having eight methylene spacers and methyl thioglycolate as linker of thiolactone ring was the most active compound with an MIC value of 1.0–4.0 µg/mL against drug sensitive and resistant strain of *M. tuberculosis*. Compound **7f** having 10 methylene spacers and bromo group as linker also showed moderate activity against *M. tuberculosis*. The other two compounds showed poor (MIC > 16.0 µg/mL) activity against sensitive and resistant strains of *M. tuberculosis*. None of the compounds were found to have significant activity against *M. avium* and *M. intracellulare* cultures (Table 1).

In conclusion, a novel series of antimycobacterial compounds have been designed and synthesized that demonstrated significant (compound **8e**) activity against drug sensitive and resistant *M. tuberculosis* cultures. The antimycobacterial activity of compound **8e** was better than isoniazid on drug resistant clinical isolates of *M. tuberculosis*. These findings clearly indicate that thialactomycin



Scheme 1. Reagents and conditions: (i) anhydrous KH, THF; (ii) PyHBr₃, acetic acid; (iii) AcSH, EtN₃, CH₂Cl₂; (iv) KOH, H₂O–EtOH; (v) Br(CH₂)_nBr, anhyd K₂CO₃, acetone, reflux; (vi) RH, anhyd K₂CO₃, acetone, reflux.

Table 1. Antimycobacterial activity of thiolactone ring based analogues

Thiolactone analogues	MIC ($\mu\text{g/mL}$)				
	<i>M. tuberculosis</i> H ₃₇ Rv ATCC 27294	<i>M. tuberculosis</i> clinical isolates		<i>M. avium</i> ATCC 49601	<i>M. intracellulare</i> ATCC 13950
		Sensitive	Resistant		
7a–e	>16.0	>16.0	>16.0	>16.0	>16.0
7f	4.0	4.0–16.0	4.0–16.0	>16.0	>16.0
8a–d	>16.0	>16.0	>16.0	>16.0	>16.0
8e	1.0	1.0–4.0	1.0–4.0	8.0	4.0
8f	>16.0	>16.0	>16.0	>16.0	>16.0
9a	>16.0	>16.0	>16.0	>16.0	>16.0
9b	>16.0	>16.0	>16.0	>16.0	>16.0
9c	>16.0	>16.0	>16.0	>16.0	>16.0
9d–f	>16.0	>16.0	>16.0	>16.0	>16.0
10a–f	>16.0	>16.0	>16.0	>16.0	>16.0
Isoniazid	0.25	0.125–0.25	8.0–>16.0	>16.0	8.0

analogues containing bromo, methyl thioglycolate and 1-methyl piperazine groups as linkers resulted in good antimycobacterial activity whereas compounds containing morpholine group as linker result in loss of activity.

References and notes

- Dve, C.; Scheele, S.; Dolin, P.; Pathania, V.; Raviglione, M. C. *J. Am. Med. Assoc.* **1999**, 282, 677.
- Enarson, D. A.; Chretien, J. *Curr. Opin. Pulm. Med.* **1999**, 5, 128.
- Bishai, W. R.; Chaisson, R. E. *Clin. Chest Med.* **1997**, 18, 115.
- Cole, S. T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S. V.; Eiglmeier, K.; Gas, S.; Barry, C. E.; Tekaiia, F.; Badcock, K.; Basham, D.; Brown, D.; Chillingworth, T.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd, S.; Hornsby, T.; Jagels, K.; Krough, A.; McLean, J.; Moule, S.; Murphy, L.; Oliver, K.; Osborne, J.; Quail, M. A.; Rajandream, M. A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, J.; Squares, R.; Squares, S.; Sulston, J. E.; Taylor, K.; Whitehead, S.; Barrell, B. G. *Nature* **1998**, 393, 537.
- Kremer, L.; Basera, G. S. *Expert Opin. Investig. Drugs* **2002**, 11, 1033.
- Oishi, H.; Noto, T.; Sasaki, H.; Suzuki, K.; Hayashi, T.; Okazaki, H.; Ando, K.; Sawada, M. *J. Antibiot. (Tokyo)* **1982**, 35, 391.
- (a) Nishida, I.; Kawaguchi, A.; Yamada, M. *J. Biol. Chem.* **1986**, 99, 1447; (b) Heath, R. J.; White, S. W.; Rock, C. O. *Prog. Lipid Res.* **2001**, 40, 467; (c) Campbell, J. W.; Cronan, J. E. *Annu. Rev. Microbiol.* **2001**, 55, 305.
- Tsay, J. T.; Rock, C. O.; Jackowski, S. J. *Bacteriology* **1992**, 174, 508.
- Price, A. C.; Choi, K. H.; Heath, R. J.; Li, Z.; White, S.; Rock, C. O. *J. Biol. Chem.* **2001**, 276, 6551.
- Kremer, L.; Douglas, J. D.; Baulard, A. R.; Morehouse, C.; Guy, M. R.; Alland, D.; Dover, L. G.; Lakey, J. H.; Jacob, W. R.; Brennan, P. J.; Minnikin, D. E.; Besra, G. S. *J. Biol. Chem.* **2000**, 275, 16857.
- Douglas, J. D.; Morehouse, C.; Senior, S. J.; Phetsukri, B.; Campbell, I. B.; Besra, G. S.; Minnikin, D. E. *Microbiology* **2002**, 148, 3101.
- Senior, S. J.; Illarionov, P. A.; Gurcha, S. S.; Campbell, I. B.; Schaeffer, M. L.; Minnikin, D. E.; Besra, G. S. *Bioorg. Med. Chem. Lett.* **2003**, 13, 3685.
- Senior, S. J.; Illarionov, P. A.; Gurcha, S. S.; Campbell, I. B.; Schaeffer, M. L.; Minnikin, D. E.; Besra, G. S. *Bioorg. Med. Chem. Lett.* **2004**, 14, 373.
- Kamal, A.; Babu, A. H.; Ramana, A. V.; Sinha, R.; Yadav, J. S.; Arora, S. K. *Bioorg. Med. Chem. Lett.*, submitted for publication.
- Wang, C. L. J.; Salvino, J. M. *Tetrahedron Lett.* **1984**, 25, 5243.
- Selected spectral data for compound **7f**: ¹H NMR (200 MHz; CDCl₃) δ 1.3 (s, 3H), 1.2–1.5 (m, 10H), 1.6 (d, 3H, J = 6.6 Hz), 1.6–1.9 (m, 3H), 1.8 (s, 3H), 3.4 (t, 2H, J = 6.6 Hz), 4–4.4 (m, 3H); MS (FAB) 365 [M⁺+1]. Anal. Calcd for C₁₆H₂₇BrO₂S: C, 52.89; H, 7.49. Found: C, 52.78; H, 7.44.
- Selected spectral data for compound **8e**: ¹H NMR (200 MHz; CDCl₃) δ 1.2–1.5 (m, 11H), 1.6 (d, 3H, J = 6.6 Hz), 1.9 (s, 3H), 2.5 (s, 3H), 3.2 (s, 2H), 3.7 (s, 3H) 4–4.4 (m, 3H); MS (FAB) 361 [M⁺+1]. Anal. Calcd for C₁₇H₂₈O₄S: C, 56.63; H, 7.83. Found: C, 52.54; H, 7.79.
- Selected spectral data for compound **9a**: ¹H NMR (200MHz; CDCl₃) δ 1.6 (d, 3H, J = 6.6 Hz), 1.7 (s, 3H), 1.8–2 (m, 2H), 2.2 (s, 3H), 2.4–2.6 (m, 10H) 4–4.4 (m, 3H); MS (FAB) 285 [M⁺+1]. Anal. Calcd for C₁₄H₂₄N₂O₂S: C, 59.12; H, 8.51. Found: C, 59.08; H, 8.48.